PSFG
PCRX icon

Park Square Financial Group’s Pacira BioSciences PCRX Stock Holding History

Park Square Financial Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-85
Closed -$2.03K – 751
2025
Q2 		$2.03K Buy
+85
New +$2.14K ﹤0.01% 891

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Park Square Financial Group's PCRX Position: Q3 2025 in Review

Park Square Financial Group sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 85 shares — an estimated $2.03K sold.

Park Square Financial Group first reported a position in PCRX in Q2 2025 and held it in 1 quarter. The position peaked at $2.03K in Q2 2025. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

  • Park Square Financial Group reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 85 Pacira BioSciences shares in Q3 2025, an estimated $2.03K.
  • Park Square Financial Group first reported a position in Pacira BioSciences in Q2 2025 and held it in 1 quarter.
  • Park Square Financial Group's Pacira BioSciences position peaked at $2.03K in Q2 2025.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.